LYSA carries out several research types, all focused on lymphoma.
Clinical trials constitute the group’s first and main activity. The first trials investigated in particular the different types of chemotherapy used in lymphomas, intensive chemotherapy treatments, transplantations, and radiotherapy use.
For several years now, LYSA has been involved in clinical trials that evaluate new active treatments in lymphoma:
- These may be Phase III trials, or randomised trials, which compare the benefit of a new drug combined with or replacing standard treatment. These trials are of great importance. First, because they allow us to determine the most efficacious treatment strategies. Second, because they will enable new medicines to be registered by the health authorities so that they can then be used in daily practice in order to treat a disease
- LYSA has also dedicated itself to clinical trials that aim to evaluate the efficacy and toxicity of new medicines alone or in combination. These trials are Phase I or II trials, and they are necessary for knowing whether or not a medicine has a chance of being truly useful and for designing the subsequent Phase III trials mentioned above
By initiating these trials on new medicines, LYSA is playing its part in giving more patients in the LYSA centres fast-track access to the latest and most efficacious medicines. Around 30 clinical trials are currently in progress, with another 10 or so at the pre-project or project-in-development stage.
Indeed, for the strategic studies that have been finalised and published (more than 10), patients are invited to take part in long-term follow-up in order to allow investigators to assess whether the initial therapeutic results remain unchanged, and to detect any potential late complications of the treatments studied. LYSA is also involved in starting a long-term follow-up programme of potential adverse effects in new drugs, called SIMONAL, which is supported by The French National Agency for Medicines and Health Products Safety (ANSM) and conducted in collaboration with the University Hospital of Nice.
LYSA is also conducting numerous studies and trials aimed to evaluate the role of new imaging tools, in particular PET, in facilitating treatment adaptation based on the efficacy observed in a given individual. The ultimate goal is to deliver the most appropriate treatment quantity to each patient, and so to develop tailored, or individualised, treatments.
Biological and Anatomical-Pathological Studies
In 2014, 18 pathological studies and 11 biological studies are ongoing. More than 5 studies biological or pathological were co- funded by INCa, the French National Cancer Institute, calls for tenders ( PAIR Lymphoma programs , tender ” Translational research “… PHRC ).
Studies designed by LYSA generate rich clinical databases , biological, pathological and imaging. They
allow many transverse or retrospective studies : clinical and biological correlations, subpopulations of studies, meta-analyzes, data mining …
The following programmes can be mentioned in particular, which aim to gain a better understanding of lymphoma biology and treatment efficacy:
- BioCORAL programme: analysis of angiogenesis
- GOAL: Genetic and Outcome in Aggressive Lymphoma: targeted analysis and of the entire genome of constitutional genetic polymorphisms in cohorts of diffuse large B-cell lymphomas
- GHEDI programme: Deciphering the genetic heterogeneity of diffuse large B-cell lymphoma in the rituximab era: analysis of genetic and molecular abnormalities in samples of diffuse large B-cell lymphoma, as well as their correlations with the patients’ clinical course
- Blood Biomarkers programme (Transcriptomic and Proteomic Approach to Research into Lymphoma Blood Biomarkers): a prognostic, prospective, and multicentre study in diffuse large B-cell lymphomas
Cross-disciplinary and Ancillary Studies
The studies designed by LYSA generate rich clinical, biological, anatomical-pathological, and imaging databases. They facilitate numerous cross-disciplinary or retrospective studies, such as clinical-biological correlations, studies of subpopulations, meta-analyses, data extraction, and so on. More than a dozen ancillary projects are currently being conducted. LYSA actively contributes to international projects (meta-analyses, surrogate endpoints and so on).